目的:检测CCL18在良性前列腺增生和前列腺癌中的表达,并分析其表达水平与临床病理特征的关系。方法:通过实时荧光定量PCR检测CCL18基因在前列腺癌、前列腺增生组织中mRNA的表达情况,用免疫组化检测前列腺癌、前列腺增生标本中CCL18蛋白的表达情况。分析CCL18基因的表达水平与临床病理特征的关系。结果:前列腺癌患者组织中CCL18 mRNA显著上调,CCL18蛋白表达与前列腺癌分化程度有正相关的变化趋势, CCL18蛋白表达上调肿瘤发生发展、临床 Gleason 评分相关( P<0.05)。结论:CCL18蛋白表达与前列腺癌分化程度呈正相关趋势,检测CCL18蛋白表达水平可协助判断前列腺癌分化程度并评估预后。
Objective:To determine the expression of CCL18 in benign prostate hyperplasia ( BPH) and prostate cancer tissues, and analyze the correlation between the CCL18 expression level and pathological characteristics. Methods:The expression of CCL18 gene in prostate cancer and BPH tissues was determined by real-time fluorescent quantitative PCR. The expression of CCL18 protein in prostate cancer and BPH samples was determined by immunohistochemical method. The correlation between the expression level and pathological characteristics of CCL18 gene was analyzed. Results:The expression of CCL18 mRNA was significantly up-regluated in the prostate cancer tissues. The expression of CCL18 protein showed a trend of positive correlation with the degree of differentiation in prostate cancer cells. The up-regulation of CCL18 was also correlated with occurrence and development of tumor and the clinical Gleason score(P〈0.05). Conclusion:There is a trend of positive correlation between the expression CCL18 protein and the differentiation of prostate cancer. Measurement of CCL18 expression can favor the judgment on the differentiation of prostate cancer and the evaluation of prognosis.